Concepedia

Marc Vimolratana

MV

Statistics

Publications

11

Citations

1K

H-Index

11

Active since

2004

Affiliations

Amgen (United States)(Current)

The University of Texas Southwestern Medical Center

Marc Vimolratana is an author at Amgen (United States) specializing in medicinal chemistry, pharmacology, and drug discovery.

Publications per year

2004–2018

11

Publications

11

AMG 176, a Selective MCL1 Inhibitor, Is Effective in Hematologic Cancer Models Alone and in Combination with Established Therapies

Sean Caenepeel, Sean P. Brown, Brian Belmontes et al. · Cancer Discovery · 2018 · 419 citations · Full text

, , +14

A Potent Class of GPR40 Full Agonists Engages the EnteroInsular Axis to Promote Glucose Control in Rodents

Jian Luo, Gayathri Swaminath, Sean P. Brown et al. · PLoS ONE · 2012 · 136 citations · Full text

, , +17

Identification and Pharmacological Characterization of Multiple Allosteric Binding Sites on the Free Fatty Acid 1 Receptor

Daniel C.-H. Lin, Qi Guo, Jian Luo et al. · Molecular Pharmacology · 2012 · 119 citations · Full text

, , +17

Discovery of AM-1638: A Potent and Orally Bioavailable GPR40/FFA1 Full Agonist

Sean P. Brown, Paul J. Dransfield, Marc Vimolratana et al. · ACS Medicinal Chemistry Letters · 2012 · 89 citations · Full text

, , +17

Discovery and Optimization of Potent GPR40 Full Agonists Containing Tricyclic Spirocycles

Yingcai Wang, Jiwen Liu, Paul J. Dransfield et al. · ACS Medicinal Chemistry Letters · 2013 · 81 citations · Full text

, , +17

1–5 of 11